Drug intelligence / Profile preview

WT1-mRNA

Development stage: Unknown
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Vaccination

Overview

WT1-mRNA is a messenger RNA encoding the Wilms' tumor protein 1 (WT1). It is utilized in the development of therapeutic cancer vaccines, specifically by electroporating autologous dendritic cells to create WT1-mRNA/DC vaccines. These vaccines are designed to stimulate antigen-specific T-lymphocyte responses, targeting WT1-expressing tumor cells. Clinical studies have evaluated its feasibility, safety, immunogenicity, and clinical activity in patients with advanced solid tumors.

Targets

WT1 (Wilms tumor protein)

Beyond the preview

Go deeper on WT1-mRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WT1-mRNA.

Explore the full profile